Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:ASND

Ascendis Pharma A/S Q3 2026 Earnings Date & Estimates

Ascendis Pharma A/S logo
$227.00 +3.79 (+1.70%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$220.05 -6.95 (-3.06%)
As of 10/14/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ascendis Pharma A/S in Q3 2026

Ascendis Pharma A/S is expected to post earnings of $0.9360 per share on revenue of $411.20 million. In the same quarter a year earlier Ascendis Pharma A/S reported -$1.17 per share on revenue of $250.71 million. Ascendis Pharma A/S last reported on August 14, 2026, posting $1.0270 per share and missing the $1.71 consensus estimate. Ascendis Pharma A/S has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.9360
Expected Revenue
$411.20 million
Prior-Year EPS
-$1.17
Prior-Year Revenue
$250.71 million
Expected Revenue Growth
+64.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.0270 (Missed by -$0.6830)
Last Quarter Revenue
$387.22 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Ascendis Pharma A/S Q3 2026 Earnings FAQ

Ascendis Pharma A/S (NASDAQ:ASND) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Ascendis Pharma A/S' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ascendis Pharma A/S to post earnings of $0.9360 per share for Q3 2026.

The consensus revenue estimate for Ascendis Pharma A/S is $411.20 million for Q3 2026.

Ascendis Pharma A/S Earnings Headlines

Ascendis Pharma A/S (NASDAQ:ASND) Raised to "Buy" at Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104172
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375624/0/en/ascendis-to-share-latest-advances-in-hypoparathyroidism-and-achondroplasia-programs-at-asbmr-2026.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)
October 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4951969/analysts-are-bullish-on-these-healthcare-stocks-ascendis-pharma-asnd-cytokinetics-cytk/
BioMarin Pharmaceutical Inc. And Ascendis Pharma A/S Enter Into Settlement And License Agreement
October 1, 2026  |  marketscreener.comM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)
September 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TXG/pressreleases/4854353/analysts-opinions-are-mixed-on-these-healthcare-stocks-ascendis-pharma-asnd-lakefront-biotherapeutics-lkft-and-10x-genomics-txg/
See More Ascendis Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email.

About Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism. Skytrofa is marketed in the United States and other selected markets, while Yorvipath has received regulatory approval in the United States and Europe.

The company also maintains a development pipeline addressing additional rare endocrine conditions, including investigational therapies based on its TransCon platform. Ascendis Pharma was founded in 2006 and is headquartered in Copenhagen, Denmark, with operations in the United States. Jan Mikkelsen serves as president and chief executive officer.

View Ascendis Pharma A/S Profile
Earnings Tools